Notice: This company has been marked as potentially delisted and may not be actively trading. SeqLL (SQL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrends SQL vs. BIAFW, PRENW, SQLLW, STRRP, VIRX, ENSC, PETV, ADXN, ICU, and BFRIShould you be buying SeqLL stock or one of its competitors? The main competitors of SeqLL include bioAffinity Technologies (BIAFW), Prenetics Global (PRENW), SeqLL (SQLLW), Star Equity (STRRP), Viracta Therapeutics (VIRX), Ensysce Biosciences (ENSC), PetVivo (PETV), Addex Therapeutics (ADXN), SeaStar Medical (ICU), and Biofrontera (BFRI). These companies are all part of the "medical" sector. SeqLL vs. bioAffinity Technologies Prenetics Global SeqLL Star Equity Viracta Therapeutics Ensysce Biosciences PetVivo Addex Therapeutics SeaStar Medical Biofrontera SeqLL (NASDAQ:SQL) and bioAffinity Technologies (NASDAQ:BIAFW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Is SQL or BIAFW more profitable? bioAffinity Technologies' return on equity of 0.00% beat SeqLL's return on equity.Company Net Margins Return on Equity Return on Assets SeqLLN/A -124.09% -64.18% bioAffinity Technologies N/A N/A N/A Does the media refer more to SQL or BIAFW? In the previous week, bioAffinity Technologies had 2 more articles in the media than SeqLL. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for SeqLL. bioAffinity Technologies' average media sentiment score of 0.87 beat SeqLL's score of 0.67 indicating that bioAffinity Technologies is being referred to more favorably in the news media. Company Overall Sentiment SeqLL Positive bioAffinity Technologies Positive Which has higher valuation and earnings, SQL or BIAFW? bioAffinity Technologies has higher revenue and earnings than SeqLL. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeqLL$80K0.00-$4.09M-$16.40N/AbioAffinity Technologies$9.37MN/AN/AN/AN/A Do insiders and institutionals have more ownership in SQL or BIAFW? 1.8% of SeqLL shares are held by institutional investors. 22.3% of SeqLL shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SQL or BIAFW? SeqLL received 1 more outperform votes than bioAffinity Technologies when rated by MarketBeat users. CompanyUnderperformOutperformSeqLLOutperform Votes1100.00% Underperform VotesNo VotesbioAffinity TechnologiesN/AN/A SummarybioAffinity Technologies beats SeqLL on 5 of the 8 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get SeqLL News Delivered to You Automatically Sign up to receive the latest news and ratings for SQL and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SQL vs. The Competition Export to ExcelMetricSeqLLDiagnostics & Research IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.12M$27.75M$5.14B$9.08BDividend YieldN/A5.44%5.09%4.23%P/E Ratio-0.312.0090.1317.20Price / SalesN/A2,398.621,117.09117.04Price / CashN/A11.4243.1037.85Price / BookN/A3.044.784.78Net Income-$4.09M$53.40M$120.31M$225.60M SeqLL Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SQLSeqLLN/AN/AN/AN/A$2.12M$80,000.00-0.317News CoverageBIAFWbioAffinity TechnologiesN/A$0.52+8.1%N/A+487.1%$0.00$9.37M0.0010News CoveragePRENWPrenetics GlobalN/A$0.01-17.2%N/AN/A$0.00$25.56M0.001Positive NewsGap DownSQLLWSeqLLN/A$0.01+18.1%N/AN/A$0.00$1,177.000.007STRRPStar EquityN/A$9.11flatN/AN/A$0.00$50.38M0.00171VIRXViracta Therapeutics2.5274 of 5 stars$0.21+4.6%$5.00+2,258.5%-56.7%$8.43MN/A-0.1820ENSCEnsysce Biosciences0.0853 of 5 stars$6.41+14.1%N/A-49.1%$8.37M$2.23M-0.2010PETVPetVivoN/A$0.41-0.9%N/A-61.2%$8.36M$970,000.00-0.8520News CoverageGap UpADXNAddex Therapeutics2.0212 of 5 stars$7.85-1.9%$30.00+282.2%+39.1%$8.32M$556,045.00-23.5330ICUSeaStar Medical0.1031 of 5 stars$1.84-7.5%N/A-81.6%$8.21M$68,000.00-0.172BFRIBiofrontera1.4434 of 5 stars$1.04-1.9%$7.00+573.1%-69.7%$8.06M$35.36M-0.4770Gap Down Related Companies and Tools Related Companies BIAFW Alternatives PRENW Alternatives SQLLW Alternatives STRRP Alternatives VIRX Alternatives ENSC Alternatives PETV Alternatives ADXN Alternatives ICU Alternatives BFRI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SQL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SeqLL Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SeqLL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
